Filing Flows

Filing Flows › Companies › Pediatrix Medical Group › Cash flow

Pediatrix Medical Group cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$113M in Q3 2026 · $210M over twelve months

Operating cash flow$117M
Capital spending−$4.4M
Free cash flow+$113M
Cash / net income2.5×

Analysis

In Q3 2026, Pediatrix Medical Group generated $117M of operating cash flow and spent $4.4M on capital projects, leaving free cash flow of $113M. That is $19.0M less than in Q3 2025 ($132M).

Over the twelve months to Sep 30, 2026, operating cash flow was $227M; the largest uses were buybacks ($211M), other financing ($25.8M), capital spending ($17.3M); besides operations, cash came from other investing ($7.4M), shares issued ($2.9M); the cash balance fell by $28.1M.

Operating cash flow was $117M against net income of $47.0M — 2.5× profit, cash ran ahead of reported earnings. The largest differences: employee-related liabilities −$47.7M, payables +$43.1M, deferred taxes +$14.1M.

Free cash flow

Pediatrix Medical Group: free cash flow by quarterPediatrix Medical Group: free cash flow by quarter$130MQ4 2024−$121MQ1 2025$133MQ2 2025$132MQ3 2025$109MQ4 2025−$136MQ1 2026$124MQ2 2026$113MQ3 2026
Operating cash flow less capital spending.
Pediatrix Medical Group: operating cash flow against capital spendingPediatrix Medical Group: operating cash flow against capital spendingOperating cash flowCapital spending$133M$3.4MQ4 2024−$117M$3.3MQ1 2025$137M$4.5MQ2 2025$137M$5.3MQ3 2025$114M$5.3MQ4 2025−$130M$6.2MQ1 2026$125M$1.4MQ2 2026$117M$4.4MQ3 2026
Latest (Q3 2026): Operating cash flow $117M, Capital spending $4.4M.

Capital allocation, year by year

Pediatrix Medical Group: where the cash came from (up) and went (down), by fiscal yearPediatrix Medical Group: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow $76.7MFY2021: Net borrowing −$760MFY2021: Shares issued $6.9MFY2021: Capital spending −$32.2MFY2021: Acquisitions −$29.9MFY2021: Buybacks −$4.7M$83.6MFY2021FY2022: Operating cash flow $167MFY2022: Net borrowing −$393MFY2022: Shares issued $5.4MFY2022: Capital spending −$29.7MFY2022: Acquisitions −$28.2MFY2022: Buybacks −$88.5M$172MFY2022FY2023: Operating cash flow $137MFY2023: Net borrowing −$4.0MFY2023: Shares issued $4.9MFY2023: Capital spending −$33.3MFY2023: Acquisitions −$6.7MFY2023: Buybacks −$919K$142MFY2023FY2024: Operating cash flow $207MFY2024: Shares issued $3.6MFY2024: Capital spending −$22.0MFY2024: Acquisitions −$8.2MFY2024: Buybacks −$1.7M$210MFY2024FY2025: Operating cash flow $271MFY2025: Shares issued $3.2MFY2025: Capital spending −$18.5MFY2025: Acquisitions −$23.2MFY2025: Buybacks −$86.7M$274MFY2025
Over these 5 years operating cash flow totalled $859M; the largest uses were net borrowing ($1.2B) and buybacks ($183M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$426M
Debt$578M
Net debt$152M
Due within a year$180M

Pediatrix Medical Group funds itself: free cash flow was $210M over the last twelve months, and $426M of cash and investments stands against $578M of debt ($180M due within a year, 2.4× covered by cash).

Where the cash came from and went

Pediatrix Medical Group: sources (+) and uses (−) of cash, Q3 2026Pediatrix Medical Group: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$117MBuybacks−$83.0MCash drawn (+) / kept (−)−$23.0MOther financing−$7.3MCapital spending−$4.4MShares issued$678KOther investing−$262K
Pediatrix Medical Group: sources (+) and uses (−) of cash, TTM to Q3 2026Pediatrix Medical Group: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$227MBuybacks−$211MCash drawn (+) / kept (−)$28.1MOther financing−$25.8MCapital spending−$17.3MAcquisitions−$11.0MOther investing$7.4MShares issued$2.9M

From profit to cash

Pediatrix Medical Group: net income to operating cash flow, Q3 2026Pediatrix Medical Group: net income to operating cash flow, Q3 2026Net income$47.0MDepreciation & amortization$6.2MStock-based pay$6.2MDeferred taxes$14.1MOther non-cash−$2.0MReceivables−$4.2MPayables$43.1MEmployee-related liabilities−$47.7MPrepaid and other assets−$266KOther liabilities−$2.4MIncome taxes payable$3.5MOperating cash flow$117M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingAcquisitionsBuybacksShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$117M−$4.4M—−$83.0M$678K−$23.0M$113M
Q2 2026$125M−$1.4M—−$42.7M$1.1M−$83.1M$124M
Q1 2026−$130M−$6.2M−$7.0M−$21.5M$544K$169M−$136M
Q4 2025$114M−$5.3M−$4.0M−$64.0M$646K−$35.2M$109M
Q3 2025$137M−$5.3M−$19.2M−$20.9M$700K−$115M$132M
Q2 2025$137M−$4.5M—−$209K$1.2M−$126M$133M
Q1 2025−$117M−$3.3M—−$1.6M$662K$131M−$121M
Q4 2024$133M−$3.4M—−$643K$732K−$126M$130M

Pediatrix Medical Group: income statement and cash flow

Pediatrix Medical Group, Q3 2026: revenue $501M (+2% year over year), operating margin 13.0%. The chart follows the revenue to costs, profit and cash.

Pediatrix Medical Group: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.